.jpg)
.png)
Dr. Soffer:
Greetings from Philadelphia. Dr. Saseen and I are very excited to be the new editors of the LipidSpin. Like many of you, I am a long-time reader and occasional contributor, and I consider it a great honor to be entrusted with this responsibility.
As the editors, Joe and I are charged with the task of curating a forum that serves as the member voice of the NLA.
Article By:
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA Diplomate, American Board of Clinical Lipidology
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO Diplomate, Accreditation Council of Clinical Lipidology
Welcome to the Fall issue of the LipidSpin. It is a great honor and privilege to have the opportunity to serve as the president of the Pacific Lipid Association (PLA) during the coming year.
Article By:
Knight Cardiovascular Institute
Associate Professor, Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health & Science University
Portland, OR
On July 24, 2015, the United States Food and Drug Administration approved the clinical use of the PCSK9 inhibitor, alirocumab, as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. On Aug. 27, 2015, evolocumab was approved for the above indications and for treatment of patients with homozygous familial hypercholesterolemia (HoFH).
Article By:
Associate Professor of Medicine
University of Miami School of Medicine
Director, Lipid Clinic and Cardiovascular Risk Reduction Program
Miami, FL Diplomate, American Board of Clinical Lipidology
The American Academy of Pediatrics recently released an update to its Recommendations for Preventive Pediatric Health Care, also known as the periodicity schedule, which will publish in the January 2016 issue of Pediatrics (published online Dec. 7).
Pledges to the Foundation of the National Lipid Association
The Foundation of the National Lipid Association is proud to announce that the 2015 Scientific Sessions this past June in Chicago was an enormous success. The Foundation event, “Lipidpalooza,” was held at the House of Blues and featured the Foundation’s own Dr. Alan Brown and his band “This End Up.” The turnout was great, and everyone had a wonderful time.
Article By:
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology
Dr. Kevin Maki was interested in studying heart disease and diabetes from an early age. Seeing his father and father’s siblings suffer from cardiovascular disease influenced him to begin researching the causes of heart disease while he was still in high school. He quickly became convinced that it was preventable. This was supported during Dr.
Article By:
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL
Diplomate, Accreditation Council for Clinical Lipidology
Lipoprotein apheresis is a technique that was first described in 1975. It involves the removal of low-density lipoprotein (LDL) and lipoprotein(a) [Lp(a)] particles from whole blood or plasma. This technique is similar to other apheresis techniques in that the blood is run through a filtering device that uses adsorption, filtration, or precipitation to remove LDL and Lp(a) particles from plasma.
Article By:
Director, Division of Cardiology
Advocate Heart Institute at Advocate Lutheran General Hospital
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology
Case:
The patient is a 53-year-old Caucasian male who comes to the cardiovascular prevention clinic with a request: “I am five years from the age at which my father died from a heart attack and I want to know what my risk is for a similar heart attack. I am not ready yet to take a statin, because it increases the risk for diabetes.”
Article By:
Division of Cardiovascular Medicine
University of Minnesota Medical School
Minneapolis, MN
Diplomate, American Board of Clinical Lipidology
University of Minnesota Medical School,
Minneapolis, MN
In 2007 I was a graduate fresh from medical school with a set of preconceived notions about what my role as a physician would be. I imagined a clinical practice busy with office visits, in-patient consultations, testing, billing, paperwork, and a general schedule similar to that of my mentors at the time. I had no idea that, during the short six years of my residency and fellowship, the world of healthcare in the U.S. was about to completely change.
Article By:
South Asian Cardiovascular Center
Advocate Heart Institute at Advocate Lutheran General Hospital
Park Ridge, IL